Evaluación y tratamiento del niño con síntomas del tracto urinario inferior (LUTS)

  • Gustavo Adolfo Guerrero-Tinoco Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias.
  • Mónica Isabel Cano-Martínez Universidad de Antioquia, Medellín.
  • Juan José Vanegas-Ruiz Hospital Pablo Tobón Uribe, Medellín.
Palabras clave: Incontinencia, Micción Disfuncional, Niño, Tracto Urinario Inferior, Vejiga

Resumen

La disfunción miccional es un trastorno del llenado o vaciado de la vejiga en niños sin alteraciones neurológicas o anatómicas. Los síntomas del tracto urinario inferior (LUTS, por la sigla en inglés de Lower urinary tract symptoms) son un motivo frecuente de consulta con el pediatra, el nefrólogo o el urólogo pediatra, e incluso con el neurólogo y el psicólogo infantil. Se le considera una enfermedad relativamente benigna lo que en ocasiones genera desinterés entre médicos y familiares y lleva a consultas tardías e interpretación inadecuada de los síntomas. Manifestaciones como urgencia, incontinencia, enuresis, goteo posmiccional, infecciones urinarias, vulvovaginitis recurrente y constipación, en un niño sin enfermedad neurológica, deben hacer pensar al médico en disfunción miccional para enfocar oportunamente el diagnóstico, restablecer la calidad de vida del paciente, evitar las infecciones urinarias y el daño renal subsecuente e irreversible secundario a un diagnóstico tardío. Las recomendaciones actuales hacen énfasis en un enfoque menos invasivo, tratamiento conservador, manejo de la constipación y reentrenamiento vesical. Este artículo discute la evaluación, el diagnóstico y el tratamiento correctos de niños con LUTS.

Descargas

La descarga de datos todavía no está disponible.

Biografía del autor/a

Gustavo Adolfo Guerrero-Tinoco, Hospital Infantil Napoleón Franco Pareja, Cartagena de Indias.
Nefrólogo Pediatra.
Mónica Isabel Cano-Martínez, Universidad de Antioquia, Medellín.
Pediatra.
Juan José Vanegas-Ruiz, Hospital Pablo Tobón Uribe, Medellín.
Nefrólogo Pediatra.

Citas

(1.) Vaz GT, Vasconcelos MM, Oliveira EA, Ferreira AL, Magalhães PG, Silva FM, et al. Prevalence of lower urinary tract symptoms in school-age children. Pediatr Nephrol. 2012 Apr;27(4):597-603. DOI 10.1007/s00467-011-2028-1.

(2.) Akil IO, Ozmen D, Cetinkaya AC. Prevalence of urinary incontinence and lower urinary tract symptoms in school-age children. Urol J. 2014 Jul;11(3):1602-8.

(3.) Ballek NK, McKenna PH. Lower urinary tract dysfunction in childhood. Urol Clin North Am. 2010 May;37(2):215-28. DOI 10.1016/j.ucl.2010.03.001.

(4.) Guerra L, Leonard M, Castagnetti M. Best practice in the assessment of ladder function in infants. Ther Adv Urol. 2014 Aug;6(4):148-64. DOI 10.1177/1756287214528745.

(5.) Clemens JQ. Basic bladder neurophysiology. Urol Clin North Am. 2010 Nov;37(4):487-94. DOI 10.1016/j.ucl.2010.06.006.

(6.) Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008 Jun;9(6):453-66. DOI 10.1038/nrn2401.

(7.) Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children’s Continence Society. J Urol. 2014 Jun;191(6):1863-65.e13. DOI 10.1016/j.juro.2014.01.110.

(8.) Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children’s Continence Society. Neurourol Urodyn. 2016 Apr;35(4):471-81. DOI 10.1002/nau.22751.

(9.) Vande Walle J, Rittig S, Bauer S, Eggert P, Marschall-Kehrel D, Tekgul S, et al. Practical consensus guidelines for the management of enuresis. Eur J Pediatr. 2012 Jun;171(6):971-83. DOI 10.1007/s00431-012-1687-7. Erratum in: Eur J Pediatr. 2013 Feb;172(2):285. Eur J Pediatr. 2012 Jun;171(6):1005.

(10.) Hoebeke P, Bower W, Combs A, De Jong T, Yang S. Diagnostic evaluation of children with daytime incontinence. J Urol. 2010 Feb;183(2):699-703. DOI 10.1016/j.juro.2009.10.038.

(11.) Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn. 2002;21(3):261-74.

(12.) Rittig S, Kamperis K, Siggaard C, Hagstroem S, Djurhuus JC. Age related nocturnal urine volume and maximum voided volume in healthy children: reappraisal of International Children’s Continence Society definitions. J Urol. 2010 Apr;183(4):1561-7. DOI 10.1016/j.juro.2009.12.046.

(13.) Plata Salazara M, Torres Castellanos L. El estudio urodinámico. Urol Colomb. 2014 Ago;23(2):128-38. DOI 10.1016/S0120-789X(14)50042-1.

(14.) Wyndaele JJ, Gammie A, Bruschini H, De Wachter S, Fry CH, Jabr RI, et al. Bladder compliance what does it represent: can we measure it, and is it clinically relevant? Neurourol Urodyn. 2011 Jun;30(5):714-22. DOI 10.1002/nau.21129.

(15.) McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol. 1981 Aug;126(2):205-9.

(16.) von Gontard A. The impact of DSM-5 and guidelines for assessment and treatment of elimination disorders. Eur Child Adolesc Psychiatry. 2013 Feb;22 Suppl 1:S61-7. DOI 10.1007/s00787-012-0363-9.

(17.) Kamperis K, Van Herzeele C, Rittig S, Vande Walle J. Optimizing response to desmopressin in patients with monosymptomatic nocturnal enuresis. Pediatr Nephrol. 2017 Feb;32(2):217-26. DOI 10.1007/s00467-016-3376-7.

(18.) Richardson I, Palmer LS. Successful treatment for giggle incontinence with biofeedback. J Urol. 2009 Oct;182(4 Suppl):2062-6. DOI 10.1016/j.juro.2009.03.021.

(19.) Yeung CK, Godley ML, Ho CK, Ransley PG, Duffy PG, Chen CN, et al. Some new insights into bladder function in infancy. Br J Urol. 1995 Aug;76(2):235-40.

(20.) Nevéus T, von Gontard A, Hoebeke P, Hjälmås K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children’s Continence Society. J Urol. 2006 Jul;176(1):314-24.

(21.) von Gontard A, Baeyens D, Van Hoecke E, Warzak WJ, Bachmann C. Psychological and psychiatric issues in urinary and fecal incontinence. J Urol. 2011 Apr;185(4):1432-6. DOI 10.1016/j.juro.2010.11.051.

(22.) Combs AJ, Grafstein N, Horowitz M, Glassberg KI. Primary bladder neck dysfunction in children and adolescents I: pelvic floor electromyography lag time--a new noninvasive method to screen for and monitor therapeutic response. J Urol [Internet]. 2005 Jan [cited 2016 Sept];173(1):[207-10]; discussion 210-1. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534705608191

(23.) Baker SS, Liptak GS, Colletti RB, Croffie JM, Di Lorenzo C, Ector W, et al. Constipation in infants and children: evaluation and treatment. A medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr. 1999 Nov;29(5):612-26. Erratum in: J Pediatr Gastroenterol Nutr 2000 Jan;30(1):109.

(24.) Chase J, Austin P, Hoebeke P, McKenna P; International Children’s Continence Society. The management of dysfunctional voiding in children: a report from the Standardisation Committee of the International Children’s Continence Society. J Urol. 2010 Apr;183(4):1296-302. DOI 10.1016/j.juro.2009.12.059.

(25.) Maternik M, Krzeminska K, Zurowska A. The management of childhood urinary incontinence. Pediatr Nephrol. 2015 Jan;30(1):41-50. DOI 10.1007/s00467-014-2791-x.

(26.) Neveus T, Eggert P, Evans J, Macedo A, Rittig S, Tekgül S, et al. Evaluation of and Treatment for Monosymptomatic Enuresis: A Standardization Document From the International Children’s Continence Society. J Urol [Internet]. 2010 Feb [cited 2016 Sept];183(2):[441-7]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534709026822

(27.) Burgers RE, Mugie SM, Chase J, Cooper CS, von Gontard A, Rittig CS, et al. Management of functional constipation in children with lower urinary tract symptoms: report from the Standardization Committee of the International Children’s Continence Society. J Urol. 2013 Jul;190(1):29-36. DOI 10.1016/j.juro.2013.01.001.

(28.) Franco I, von Gontard A, De Gennaro M; International Childrens’s Continence Society. Evaluation and treatment of nonmonosymptomatic nocturnal enuresis: a standardization document from the International Children’s Continence Society. J Pediatr Urol. 2013 Apr;9(2):234-43. DOI 10.1016/j.jpurol.2012.10.026.

(29.) Bauer SB, Austin PF, Rawashdeh YF, de Jong TP, Franco I, Siggard C, et al. International Children’s Continence Society’s recommendations for initial diagnostic evaluation and follow-up in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012 Jun;31(5):610-4. DOI 10.1002/nau.22247.

(30.) Hagstroem S, Mahler B, Madsen B, Djurhuus JC, Rittig S. Transcutaneous electrical nerve stimulation for refractory daytime urinary urge incontinence. J Urol. 2009 Oct;182(4 Suppl):2072-8. DOI 10.1016/j.juro.2009.05.101.

(31.) Monga AK, Tracey MR, Subbaroyan J. A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction. Int Urogynecol J. 2012 Aug;23(8):993-1005. DOI 10.1007/s00192-012-1691-5.

(32.) Barroso U Jr, Lordêlo P. Electrical nerve stimulation for overactive bladder in children. Nat Rev Urol. 2011 Jun;8(7):402-7. DOI 10.1038/nrurol.2011.68.

(33.) Glazener CM, Evans JH, Peto RE. Alarm interventions for nocturnal enuresis in children. Cochrane Database Syst Rev. 2005 Apr; 2):CD002911.

(34.) Hegde SS, Mammen M, Jasper JR. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies. Curr Opin Investig Drugs. 2004 Jan;5(1):40-9.

(35.) Nijman RJ. Role of antimuscarinics in the treatment of nonneurogenic daytime urinary incontinence in children. Urology. 2004 Mar;63(3 Suppl 1):45-50.

(36.) Gleason JM, Daniels C, Williams K, Varghese A, Koyle MA, Bägli DJ, et al. Single center experience with oxybutynin transdermal system (patch) for management of symptoms related to non-neuropathic overactive bladder in children: an attractive, well tolerated alternative form of administration. J Pediatr Urol. 2014 Aug;10(4):753-7. DOI 10.1016/j.jpurol.2013.12.017.

(37.) Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007 Nov;100(5):987-1006.

(38.) Jonville AP, Dutertre JP, Barbellion M, Autret E. [Adverse effects of oxybutynin chloride (Ditropan) in pediatrics]. Arch Fr Pediatr. 1993 Jan;50(1):27-9. French.

(39.) Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012 Jan;1:CD005429. DOI 10.1002/14651858.CD005429.pub2.

(40.) Bolduc S, Upadhyay J, Payton J, Bägli DJ, McLorie GA, Khoury AE, et al. The use of tolterodine in children after oxybutynin failure. BJU Int. 2003 Mar;91(4):398-401.

(41.) Hjälmås K, Hellström AL, Mogren K, Läckgren G, Stenberg A. The overactive bladder in children: a potential future indication for tolterodine. BJU Int. 2001 Apr;87(6):569-74.

(42.) Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, et al. Solifenacin for therapy resistant overactive bladder. J Urol. 2009 Oct;182(4 Suppl):2040-4. DOI 10.1016/j.juro.2009.05.100.

(43.) Bolduc S, Moore K, Nadeau G, Lebel S, Lamontagne P, Hamel M. Prospective open label study of solifenacin for overactive bladder in children. J Urol. 2010 Oct;184(4 Suppl):1668-73. DOI 10.1016/j.juro.2010.03.124.

(44.) Van de Walle J, Van Herzeele C, Raes A. Is there still a role for desmopressin in children with primary monosymptomatic nocturnal enuresis?: a focus on safety issues. Drug Saf. 2010 Apr;33(4):261-71. DOI 10.2165/11319110-000000000-00000.

(45.) De Guchtenaere A, Van Herzeele C, Raes A, Dehoorne J, Hoebeke P, Van Laecke E, et al. Oral lyophylizate formulation of desmopressin: superior pharmacodynamics compared to tablet due to low food interaction. J Urol. 2011 Jun;185(6):2308-13. DOI 10.1016/j.juro.2011.02.039.

(46.) Marschall-Kehrel D, Harms TW; Enuresis Algorithm of Marschall Survey Group. Structured desmopressin withdrawal improves response and treatment outcome for monosymptomatic enuretic children. J Urol. 2009 Oct;182(4 Suppl):2022-6. DOI 10.1016/j.juro.2009.03.068.

(47.) Ohtomo Y, Umino D, Takada M, Fujinaga S, Niijima S, Shimizu T. Gradual tapering of desmopressin leads to better outcome in nocturnal enuresis. Pediatr Int. 2015 Aug;57(4):656-8. DOI 10.1111/ped.12614.

(48.) Lucchini B, Simonetti GD, Ceschi A, Lava SA, Faré PB, Bianchetti MG. Severe signs of hyponatremia secondary to desmopressin treatment for enuresis: a systematic review. J Pediatr Urol. 2013 Dec;9(6 Pt B):1049-53. DOI 10.1016/j.jpurol.2013.02.012.

(49.) Hunsballe JM, Rittig S, Pedersen EB, Olesen OV, Djurhuus JC. Single dose imipramine reduces nocturnal urine output in patients with nocturnal enuresis and nocturnal polyuria. J Urol. 1997 Sep;158(3 Pt 1):830-6.

(50.) Mombini H. The relationship between weight as well as the kind of prostate hypertrophy and the response to Tamsulosine, a specific alpha-blocker. Urol J. 2004 Spring;1(2):115-6.

(51.) Donohoe JM, Combs AJ, Glassberg KI. Primary bladder neck dysfunction in children and adolescents II: results of treatment with alpha-adrenergic antagonists. J Urol [Internet]. 2005 Jan[cited 2016 Sept];173(1):[212-6]. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0022534705608208

(52.) DasGupta R, Murphy FL. Botulinum toxin in paediatric urology: a systematic literature review. Pediatr Surg Int. 2009 Jan;25(1):19-23. DOI 10.1007/s00383-008-2260-3.

(53.) Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int. 2007 Feb;99(2):247-62.

(54.) Hoebeke P, De Caestecker K, Vande Walle J, Dehoorne J, Raes A, Verleyen P, et al. The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol. 2006 Jul;176(1):328-30; discussion 330-1.

(55.) McDowell DT, Noone D, Tareen F, Waldron M, Quinn F. Urinary incontinence in children: botulinum toxin is a safe and effective treatment option. Pediatr Surg Int. 2012 Mar;28(3):315-20. DOI 10.1007/s00383-011-3039-5.

Publicado
2018-01-01
Sección
Artículos de revisión